ResearcherUniversity of North Carolina at CharlotteNo recent work listed

Shan Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8106-6295; OpenAlex author ID A5038395378; NIH RePORTER profile ID 9490261. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 1
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper, 1 grant

Papers 2

Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic O… Co-author DOI 10.1002/smll.202104449 ↗
APE2 Is a General Regulator of the ATR-Chk1 DNA Damage Response Pathway to Maintain Genome Integrity in Pancreatic Cancer Cells. Last author DOI 10.3389/fcell.2021.738502 ↗

Grants 1

Mechanism of APE1 in DNA damage response R01CA225637 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Md Akram Hossain · 2 shared papers, 2021–2022 · strength 0.31
- Paper Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplati… DOI 10.1002/smll.202104449 ↗
- Paper APE2 Is a General Regulator of the ATR-Chk1 DNA Damage Response Pathway to Maintain Genome Integrity in Pancreatic Canc… DOI 10.3389/fcell.2021.738502 ↗
Mubin Tarannum · 1 shared paper, 2022 · strength 0.19
- Paper Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplati… DOI 10.1002/smll.202104449 ↗
Juan Luis Vivero-Escoto · 1 shared paper, 2022 · strength 0.19
- Paper Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplati… DOI 10.1002/smll.202104449 ↗
Pinku Mukherjee · 1 shared paper, 2022 · strength 0.19
- Paper Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplati… DOI 10.1002/smll.202104449 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.